340B Insight wants to make our podcast the best it can be. To help us succeed, we’d like to hear your thoughts. Please take just a few minutes to complete our listener survey, and we will enter you in a drawing to win a $100 gift card! To participate, please go to 340bpodcast.org/survey.

Patients with behavioral health and substance use disorders often struggle with accessing and staying on the daily oral medications they need to keep their disorders controlled. That’s why SSM Health uses some of its 340B savings to run long-acting injectable (LAI) clinics in the St. Louis area to help these patients achieve better health. We speak with SSM Health Vice President of Pharmacy Financial Operations Michelle Schmitt to learn how much of a role 340B plays in that patient care mission.

LAI clinics offer comprehensive services

SSM Health’s three LAI clinics offer injections for patients with conditions such as bipolar disorder, schizophrenia, and alcohol and opioid use disorders that might last as long as three to six months. Clinic visits also give the patients access to a full team of pharmacists, psychiatrists, nurses, therapists, and others to help them navigate treatment and stay healthy.

340B funds are key to patient access

Because behavioral health is often a subsidized service, 340B savings are crucial to the operations of the clinics. They also enable SSM Health to offer financial assistance to patients living up to 400% of the poverty level so they can afford the treatments they need to stay on the road to recovery.

Cuts to 340B would be detrimental to patients

Schmitt says losing access to 340B pricing could mean a 60-70% price increase in the cost of LAI drugs, which would threaten the viability of the clinics and the financial assistance that many patients rely on to access their treatments. She says these clinics are a great example of how 340B is about much more than just price discounts; it provides resources for health systems to meet unique community health needs and serve patients where they are.

Resources

1. Federal Legislation Would Ban Harmful Drug Company Restrictions on 340B